Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri

CANBAZ KABAY, SİBEL; AYDIN, HASAN EMRE; Cetiner, Mustafa

Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri

Mustafa ÇETİNER, (Dumlupınar Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, Kütahya, Türkiye)

Sibel Canbaz KABAY, (Dumlupınar Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, Kütahya, Türkiye)

Hasan Emre AYDIN (Dumlupınar Üniversitesi Tıp Fakültesi, Nöroşirurji Anabilim Dalı, Kütahya, Türkiye)

Türk Nöroloji Dergisi

8 1

Yıl: 2017 Cilt: 23 Sayı: 4 Sayfa Aralığı: 193 - 198 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri

Öz:

Amaç: İnme ciddi derecede mortalite ve sakatlık sebebidir. Hastanın yanındaki bakım verenler de bu durumdan olumsuz etkilenir. Aynı zamanda sağlık ekonomisi üzerine büyük bir yük oluşturur. Son yıllarda iskemik inmeli hastaların akut dönemde tanı, tedavi ve bakımları açısından önemli gelişmeler kaydedilmiştir. Rekombinant doku plazminojen aktivatörünün (r-tPA) kullanıldığı intravenöz (İV) trombolitik tedavi bunlar arasındadır. Çalışmamızın amacı akut iskemik inmeli hastalarda, kliniğimizde uyguladığımız İV trombolitik tedavi sonuçlarını paylaşmaktır.Gereç ve Yöntem: Mayıs 2014 ve Haziran 2016 yılları arasında inme semptomlarının başlamasından ilk 4,5 saat içerisinde kliniğimize başvuran, iskemik inme tanısı alan ve İV trombolitik tedavi uygulanan 52 hastanın klinik verileri retrospektif olarak incelendi. Demografik özellikler ve klinik veriler kaydedildi. Bulgular: Çalışmaya alınan 52 hastanın 23'ü erkek 29'u kadın ve hastaların yaş ortalamaları 70,7±12,8 idi. Tedavi sonrası 8 hastada (%15,4) intrakraniyal kanama gözlendi. Bunlardan 6'sında (%11,5) asemptomatik, 2'sinde (%3,8) semptomatik kanama saptandı. On altı hastanın (%30,8) 3 ay sonraki modifiye Rankin Skalası (mRS) skoru 0-1, 10 hastanın (%19,2) mRS skoru 2-3, 13 hastanın (%25) mRS skoru 4-5 idi. Total anterior sirkülasyon infarktı olan 7 hastada (%20) mRS skoru , parsiyel anterior sirkülasyon infarktı olan 8 hastada (%57,1) mRS skoru 0-1 tespit edildi. Tedavi sonrası 3 aylık dönemde 13 hasta (%25) kaybedildi. Sonuç: Akut iskemik inmede ilk 4,5 saatte r-tPA ile İV trombolitik tedavi kolay uygulanır, etkili ve güvenli bir tedavidir. Uygun hasta seçimi ile inme sonucu gelişebilecek sakatlık azaltılabilir ve bağımsız yaşayan hasta sayısı arttırılabilir

Anahtar Kelime:

Konular: Tıbbi Araştırmalar Deneysel Klinik Nöroloji Nörolojik Bilimler Üroloji ve Nefroloji Hematoloji Pediatri

Intravenous Thrombolytic Therapy in Acute Ischemic Stroke: The Experience of Kütahya

Öz:

Objective: Stroke is a serious cause of mortality and disability. The caregiver of the patients may be adversely affected by this situation as well. In addition, stroke has a great economic burden on healthcare. Significant improvement has been achieved in the field of diagnosis, treatment, and care in the acute phase of the ischemic stroke in recent years. Thrombolysis with intravenous (IV) recombinant tissue type plasminogen activator (r-tPA) is the main treatment option in selected patients. The aim of our study was to share the results of intravenous (IV) thrombolytic therapy applied to patients with acute ischemic stroke in our clinic. Materials and Methods: We evaluated the clinical data of 52 patients who were admitted to our clinic with ischemic stroke within the first 4.5 hours after onset of stroke symptoms, and were treated with IV thrombolytic therapy, between the May 2014 and June 2016. Demographic characteristics and clinical data were recorded. Results: Twenty-three of the patients were male and 29 were female. The mean age was 70.7±12.8 years (range, 41-92 years). Intracranial hemorrhage after treatment was observed in 8 patients (15.4%). Of these, 6 patients (11.5%) had asymptomatic hemorrhage, 2 patients (3.8%) had symptomatic hemorrhage. The mean score of modified Rankin Scale (mRS) was 0-1 in 16 (30.8%) patients, 2-3 in 10 (19.2%) patients, and 4-5 in 13 (25%) patients. The mean mRS score of 7 (20%) patients with total anterior circulation infarct was 0-1. The mean mRS score of 8 (57.1%) patients with partial anterior circulation infarct was 0-1. Thirteen (25%) patients died within 3 months of the treatment. Conclusion: Intravenous thrombolytic therapy is an effective and safe treatment that is easy to administer within 4.5 hours in patients with acute ischemic stroke. This treatment increases the number of ambulatory patients and reduces disability in selected patients

Anahtar Kelime:

Konular: Tıbbi Araştırmalar Deneysel Klinik Nöroloji Nörolojik Bilimler Üroloji ve Nefroloji Hematoloji Pediatri

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Blackham KA, Meyers PM, Abruzzo TA, Albuquerque FC, Fiorella D, Fraser J, Frei D, Gandhi CD, Heck DV, Hirsch JA, Hsu DP, Hussain MS, Javaraman M, Narayanan S, Prestigiacomo C, Sunshine JL; Society for NeuroInterventional Surgery. Endovascular therapy of acute ischemic stroke: report of the standards of practice committee of the society of neurointerventional surgey. J Neurointerv Surg 2012;4:87-93.
2. Wolf PA, Kannel WB, Mc Gee DL. Epidemiology of strokes in North America. In: Barnett HJM, Stein BM, Mohr JP, Yatsu FM, (eds). Stroke: Pathophysiology, Diagnosis and Management. New York: Churchill Livingstone, 1986:19-29.
3. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, Kaste M, Lipka LJ, Pedraza S, Ringleb PA, Rowley HA, Schneider D, Schwamm LH, Leal JS, Söhngen M, Teal PA, Wilhelm-Ogunbiyi K, Wintermark M, Warach S. Intravenous desmoteplase in patients with acute ischemic stroke selected by MRI perfusion- diffusion weighted imaging or perfusion CT (DIAS- 2): A prospective, randomized, double-blind, placebo controlled study. Lancet Neurol 2009;8:141-150.
4. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
5. Furlan AJ, Eyding D, Albers GW, Al-Rawi Y, Less KR, Rowley HA, Sachara C, Soehngen M, Warach S, Hacke W; DEDAS Investigators. Dose escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006;37:1227- 1231.
6. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, Albers GW, Kaste M, Marler JR, Hamilton SA, Tilley BC, Davis SM, Donnan GA, Hacke W; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group, Allen K, Mau J, Meier D, del Zoppo G, De Silva DA, Butcher KS, Parsons MW, Barber PA, Levi C, Bladin C, Byrnes G. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS and EPITHET trials. Lancet 2010;375:1695- 1703.
7. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke. A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2013;44:870-947.
8. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahigren N, Toni D; ECASS Investigators. Thrombolysis with alteplase 3 to 4,5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
9. Michaels AD, Spinler SA, Leeper B, Ohman EM, Alexande KP, Newby LK, Ay H, Gibler WB; American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology, Council on Quality of Care and Outcomes Research; Council on Cardiopulmonary, Critical Care, Perioperative, and Resuscitation; Council on Cardiovascular Nursing; Stroke Council. Medication errors in acute cardiovascular and stroke patients: a scientific statement from the American Heart Assocition. Circulation 2010;121:1664-1682.
10. Saver JL. Time is brain--quantified. Stroke 2006;37:263-266.
11. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, Olson DM, Hernandez AF, Peterson ED, Schwamm LH. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 2013;309:2480-2488.
12. Bock BF. Proceedings of a National Symposium Rapid Identification and Treatment of Acute Stroke: Response System for Patients Presenting With Acute Stroke. http://www.ninds.nih.gov/news_and_events/proceedings/ stroke_proceedings/bock.htm. Accessed: 23.08.2011.
13. Kutluk K, Kaya D, Afsar N, Arsava EM, Ozturk V, Uzuner N, Giray S, Topcuoglu MA, Gungor L, Sirin H, Yaka E, Ozdemir O, Dalkara T; Turkish Thrombolysis Study Group. Analyses of the Turkish National Intravenous Thrombolysis Registry. J Stroke Cerebrovasc Dis 2016;25:1041-1047.
14. Barreto AD, Alexandrov AV. Adjunctive and alternative approaches to current reperfusion therapy. Stroke 2012;43:591-598.
15. del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA Busse O, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol 1992;32:78-86.
16. Saqqur M, Uchino K, Demchuk AM, Molina CA, Garami Z, Calleja S, Akhtar N, Orouk FO, Salam A, Shuaib A, Alexandrov AV; CLOTBUST Investigators. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke 2007;38:948-954.
17. Von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke 1992;23:646-652.
18. Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology 1992;42:976-982.
19. Hacke W, Zeumer H, Ferbert A, Bruckmann H, Zoppo GJ. Intra-arterial thrombolytic therapy improves outcome in patients with acute vertebrobasilar occlusive disease. Stroke 1988;19:1216-1222.
20. Okada Y, Sadoshima S, Nakane H, Utsunomiya H, Fujishima M. Early computed tomographic findings for thrombolytic therapy in patients with acute brain embolism. Stroke 1992;23:20-23.
21. Brandt T, von Kummer R, Müller-Küppers M, Hacke W. Thrombolytic therapy of acute basilar artery occlusion: variables affecting recanalisation and outcome. Stroke 1996;27:875-881.
22. Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant Tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke. JAMA 1999;282:2019-2026.
23. Yaghi S, Boehme AK, Dibu J, Leon Guerrero CR, Ali S, Martin-Schild S, Sands KA, Noorian AR, Blum CA, Chaudhary S, Schwamm LH, Liebeskind DS, Marshall RS, Willey JZ. Treatment and outcome of ThrombolysisRelated Hemorrhage. JAMA Neurol 2015;72:1451-1457.
24. Di Carlo A, Lamassa M, Baldereschi M, Pracucci G, Consoli D, Wolfe CD, Giroud M, Rudd A, Burger I, Ghetti A, Inzitari D; European BIOMED Study of Stroke Care Group. Risk factors and outcome of subtypes of ischemic stroke. Data from a multicenter multinational hospital-based registry. The European Community Stroke Project. J Neurol Sci 2006;244:143

APA	Cetiner M, CANBAZ KABAY S, AYDIN H (2017). Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri. , 193 - 198.
Chicago	Cetiner Mustafa,CANBAZ KABAY SİBEL,AYDIN HASAN EMRE Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri. (2017): 193 - 198.
MLA	Cetiner Mustafa,CANBAZ KABAY SİBEL,AYDIN HASAN EMRE Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri. , 2017, ss.193 - 198.
AMA	Cetiner M,CANBAZ KABAY S,AYDIN H Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri. . 2017; 193 - 198.
Vancouver	Cetiner M,CANBAZ KABAY S,AYDIN H Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri. . 2017; 193 - 198.
IEEE	Cetiner M,CANBAZ KABAY S,AYDIN H "Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri." , ss.193 - 198, 2017.
ISNAD	Cetiner, Mustafa vd. "Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri". (2017), 193-198.

APA	Cetiner M, CANBAZ KABAY S, AYDIN H (2017). Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri. Türk Nöroloji Dergisi, 23(4), 193 - 198.
Chicago	Cetiner Mustafa,CANBAZ KABAY SİBEL,AYDIN HASAN EMRE Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri. Türk Nöroloji Dergisi 23, no.4 (2017): 193 - 198.
MLA	Cetiner Mustafa,CANBAZ KABAY SİBEL,AYDIN HASAN EMRE Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri. Türk Nöroloji Dergisi, vol.23, no.4, 2017, ss.193 - 198.
AMA	Cetiner M,CANBAZ KABAY S,AYDIN H Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri. Türk Nöroloji Dergisi. 2017; 23(4): 193 - 198.
Vancouver	Cetiner M,CANBAZ KABAY S,AYDIN H Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri. Türk Nöroloji Dergisi. 2017; 23(4): 193 - 198.
IEEE	Cetiner M,CANBAZ KABAY S,AYDIN H "Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri." Türk Nöroloji Dergisi, 23, ss.193 - 198, 2017.
ISNAD	Cetiner, Mustafa vd. "Akut İskemik İnmede İntravenöz Trombolitik Tedavi: Kütahya Deneyimleri". Türk Nöroloji Dergisi 23/4 (2017), 193-198.